Month: October 2023
-
PBAC to PBS gap under fire
- 27 Oct 2023
PBS listings, industry conflicts of interest and 60-day prescribing were among key topics interrogated at Senate Estimates.
Read more -
Lilly Alzheimer therapy under TGA review
- 27 Oct 2023
Brand name revealed as Lilly chases Eisai, another siRNA comes under review, and a new Janssen combo arrives.
Read more -
MSAC ranks continue to shrink
- 27 Oct 2023
Five members including a Deputy Chair have departed the committee in recent months as its Chair’s term also nears an end.
Read more -
When women behave badly
- 27 Oct 2023
Exchanges between Senators Katy Gallagher and Anne Ruston in Senate Estimates resembled an episode of Mean Girls.
Read more -
Four step on to MA Board
- 25 Oct 2023
Three new directors join returning Vice Chair Anne Harris as the Medicines Australia Board looks to drive sector change. Exclusive director comments.
Read more -
Roche Aust names incoming GM
- 25 Oct 2023
As Stuart Knight prepares to finish his time at the helm, the Swiss pharma giant has called on another New Zealander to take his place.
Read more -
Way paved for new funding pathway
- 25 Oct 2023
Adelaide pumps out two more draft papers, one on clinical evaluation methods and the other on comparators and outcomes.
Read more -
Swedish pharma hits funding hurdle
- 25 Oct 2023
Hansa Biopharma argues reimbursement committee’s use of off-label comparators inappropriate for assessing transplant therapy.
Read more








